SEC Form SC 13G filed by Haemonetics Corporation

11/14/24 1:28:29 PM ET

Medical/Dental Instruments

Health Care

Get the next $HAE alert in real time by email

SC 13G 1 hae13gsep24.txt UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ) HAEMONETICS CORP/MASS (Name of Issuer) COMMON STOCK (Title of Class of Securities) 405024100 (CUSIP NUMBER) September 30, 2024 (Date of Event which Requires Filing of Statement) Check the appropriate box to designate the Rule pursuant to which this Schedule is filed: [x] Rule 13d - 1(b) Rule 13d - 1(c) Rule 13d - 1(d) 1. Name of Reporting Person T. Rowe Price Investment Management, Inc. 85-4328500 2. Check the Appropriate Box if a Member of a Group NOT APPLICABLE 3. SEC Use Only 4. Citizenship or Place of Organization Maryland Number of Shares Beneficially Owned by Each Reporting Person With 5. Sole Voting Power* 2,850,637 6. Shared Voting Power* 0 7. Sole Dispositive Power* 2,850,637 8. Shared Dispositive Power 0 9. Aggregate Amount Beneficially Owned by Each Reporting Person 2,850,637 10. Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares NOT APPLICABLE 11. Percent of Class Represented by Amount in Row 9 5.6% 12. Type of Reporting Person IA *Any shares reported in Items 5 and 6 are also reported in Item 7. Item 1(a) Name of Issuer: HAEMONETICS CORP/MASS Item 1(b) Address of Issuer's Principal Executive Offices: 125 SUMMER STREET, BOSTON, MA 02110 Item 2(a) Name of Person(s) Filing: (1) T. Rowe Price Investment Management, Inc. (Price Investment Management) Item 2(b) Address of Principal Business Office: 101 E. Pratt Street, Baltimore, MD 21201 Item 2(c) Citizenship or Place of Organization: (1) Maryland Item 2(d) Title of Class of Securities: COMMON STOCK Item 2(e) Cusip Number: 405024100 Item 3: The person filing this Schedule 13G is an: X Investment Adviser registered under Section 203 of the Investment Advisers Act of 1940 Item 4: Reference is made to Items 5-11 on the preceding pages of this Schedule 13G. Item 5: Ownership of Five Percent or Less of a Class Not Applicable Item 6: Ownership of More than Five Percent on Behalf of Another Person (1) Price Investment Management does not serve as custodian of the assets of any of its clients; accordingly, in each instance only the client or the client's custodian or trustee bank has the right to receive dividends paid with respect to, and proceeds from the sale of, such securities. The ultimate power to direct the receipt of dividends paid with respect to, and the proceeds from the sale of, such securities, is vested in the individual and institutional clients which Price Investment Management serves as investment adviser. Any and all discretionary authority which has been delegated to Price Investment Management may be revoked in whole or in part at any time. Except as may be indicated if this is a joint filing with one of the registered investment companies sponsored by Price Investment Management which it also serves as investment adviser ("T. Rowe Price Funds"), not more than 5% of the class of such securities is owned by any one client subject to the investment advice of Price Investment Management. Item 7: Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. Not Applicable Item 8: Identification and Classification of Members of the Group Not Applicable Item 9: Notice of Dissolution of Group Not Applicable Item 10: Certification By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. T. Rowe Price Investment Management, Inc. hereby declares and affirms that the filing of Schedule 13G shall not be construed as an admission that Price Investment Management is the beneficial owner of the securities referred to, which beneficial ownership is expressly denied. Signature. After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. T. Rowe Price Investment Management, Inc. Date: November 14, 2024 Signature: /s/ Ellen York Name & Title: Ellen York, Vice President 09/30/2024

Get the next $HAE alert in real time by email

Recent Analyst Ratings for

$HAE

Date	Price Target	Rating	Analyst
2/7/2025	$95.00 → $68.00	Neutral → Underperform	BofA Securities
12/6/2024	$116.00	Overweight	Analyst
11/8/2024	$120.00	Outperform → Strong Buy	Raymond James
9/13/2024	$116.00	Buy	CL King
9/11/2024	$85.00	Neutral	BofA Securities
9/10/2024	$112.00	Buy	BTIG Research
6/12/2024	$112.00	Hold → Buy	Needham
10/13/2022	$90.00	Buy	Mizuho

More analyst ratings

SEC Form SC 13G filed by Haemonetics Corporation

Chat with this insight

Recent Analyst Ratings for
$HAE

$HAE
Press Releases

Fastest customizable press release news feed in the world

Haemonetics 4th Quarter and Fiscal Year 2025 Earnings Release Available on Investor Relations Website

Vivasure Medical Receives CE Mark Approval in Europe for PerQseal Elite Vascular Closure System

Haemonetics Sets Date for Publishing Fourth Quarter and Fiscal Year 2025 Results: May 8, 2025

$HAE
SEC Filings

Haemonetics Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Costs Associated with Exit or Disposal Activities, Financial Statements and Exhibits

Haemonetics Corporation filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

SEC Form 10-Q filed by Haemonetics Corporation

$HAE
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Haemonetics downgraded by BofA Securities with a new price target

Analyst initiated coverage on Haemonetics with a new price target

Haemonetics upgraded by Raymond James with a new price target

$HAE
Financials

Live finance-specific insights

Haemonetics 4th Quarter and Fiscal Year 2025 Earnings Release Available on Investor Relations Website

Haemonetics Sets Date for Publishing Fourth Quarter and Fiscal Year 2025 Results: May 8, 2025

Haemonetics 3rd Quarter Fiscal Year 2025 Earnings Release Available on Investor Relations Website

$HAE
Leadership Updates

Live Leadership Updates

Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Hardean Achneck, MD as Chief Medical Officer

Sotera Health Appoints Christopher Simon to the Board of Directors

Haemonetics Appoints Roy Galvin as President, Global Plasma and Blood Center

$HAE
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

EVP, Chief Financial Officer Darecca James covered exercise/tax liability with 654 shares, decreasing direct ownership by 4% to 16,692 units (SEC Form 4)

SEC Form 3 filed by new insider Chan Frank

President, Global Plasma & BC Galvin Roy covered exercise/tax liability with 161 shares, decreasing direct ownership by 2% to 7,373 units (SEC Form 4)

$HAE
Large Ownership Changes

This live feed shows all institutional transactions in real time.